SAN DIEGO, Feb. 6 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA),
a company focused on commercializing technologies and products for
accelerating drug discovery and development, today announced that it would
convene a Special Meeting of Stockholders on March 12, 2001 at 10:00 AM
pacific standard time to consider the proposed acquisition of Trega by LION
bioscience AG and other matters as may properly come before the meeting.
Stockholders of record on February 6, 2001 will be entitled to notice of, and
to vote at, the Special Meeting and any adjournments thereof. The meeting
will be held at Trega's corporate office at 9880 Campus Point Drive, San
Diego, California. The proxy statement relating to the Special Meeting will
be mailed to stockholders on or around February 15, 2001. Copies of the proxy
statement can also be obtained by contacting Trega's Investor Relations
department at 858-410-6601.
Trega Biosciences, Inc. (Nasdaq: TRGA) is a premier provider of products
that accelerate and improve drug discovery through its iDiscovery(TM)
technologies linking biology and chemistry with information technologies.
Trega's iDEA(TM) family of information-based models simulate, in silico, how
drug candidates will be processed in the body, thereby enabling selection of
those with optimal characteristics for clinical development. Together with
its iDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced
small molecules are designed to facilitate the identification and optimization
of drug candidates.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the requisite approval of Trega's
stockholders will be received in connection with the proposed acquisition of
Trega by LION and other risks detailed from time to time in Trega's Securities
and Exchange Commission filings. These forward-looking statements represent
Trega's judgment as of the date of this release. Trega disclaims, however,
any intent or obligation to update these forward-looking statements.
SOURCE Trega Biosciences, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President, Finance &
CFO, 858-410-6695, or Cynthia Reindal, Corp. Communications &
Investor Relations, 858-410-6601, both of Trega Biosciences, Inc.
|
